https://www.urologytimes.com/view/adjuvant-atezolizumab-falls-short-in-renal-cell-carcinoma
0
0
9/11/22 at 2:06am
Organization
Urologytimes.com
Author
Jason M. Broderick
The double-blind phase 3 IMmotion010 trial randomized patients with resected renal cell carcinoma at increased risk of recurrence to adjuvant atezolizumab or placebo.
Create an account
or login to join the discussion